2-(prop-2-yn-1-yl)pent-4-yn-1-yl 3-hydroxybenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(prop-2-yn-1-yl)pent-4-yn-1-yl 3-hydroxybenzoate
• 英文别名: 2-Prop-2-ynylpent-4-ynyl 3-hydroxybenzoate；2-prop-2-ynylpent-4-ynyl 3-hydroxybenzoate
• 化学式: C₁₅H₁₄O₃
• 分子量: 242.274
• InChiKey: VSZFMTRRMPBJCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(prop-2-yn-1-yl)pent-4-yn-1-yl 3-hydroxybenzoate 、 酮咯酸 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 以71%的产率得到3-(((2-(prop-2-yn-1-yl)pent-4-yn-1-yl)oxy)carbonyl)phenyl 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate
  参考文献：
  名称：

  [EN] POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT
  [FR] CONJUGUÉ DE POLYMÈRE COMPRENANT UN AGENT BIOACTIF

  摘要：

  本发明一般涉及聚合物-生物活性剂共轭物，用于向受试者递送生物活性剂。该聚合物-生物活性剂共轭物在聚合物骨架中含有三唑基团和从喹诺酮、非甾体类抗炎药和二者混合物中选择的生物活性基团。本发明还涉及使用点击环加成化学反应制备聚合物共轭物的方法，适用于制备聚合物共轭物的单体-生物活性剂共轭物，以及包含聚合物共轭物的药品产品，用于术后护理以治疗或预防感染、提供镇痛和治疗炎症。

  公开号：

  WO2017041142A1

文献信息

• [EN] BIODEGRADABLE DRUG-POLYMER CONJUGATE<br/>[FR] CONJUGUÉ MÉDICAMENT-POLYMÈRE BIODÉGRADABLE
  申请人：POLYACTIVA PTY LTD

  公开号：WO2021051149A1

  公开（公告）日：2021-03-25

  A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable bicyclic prostaglandin; L is a linker group group; and at least one co-monomer of Formula III J-( Y1 –A)n, J represents a linking functional group, n is 2 to 8 preferably 3 to 8; Y1 comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched C1 to C10 alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.

  一种药物-聚合物共轭物，其中是至少一个式(I)的单体的共聚物，其中：X在每次出现时可以相同也可以不同，表示包含炔烃或叠氮基团的末端官能团；Q在每次出现时独立选择，可以存在也可以不存在，当存在时，表示一个连接基团；R从由线性或支链烃烃基、可选择地取代的芳基和可选择地取代的杂环芳基组成的群体中选择；D是可释放的双环前列腺素；L是连接基团；以及至少一个式III J-(Y1-A)n的共单体，其中J表示连接官能团，n为2至8，最好为3至8；Y1包括一个式(ORa)m的聚醚，其中Ra独立地为乙烯、丙烯和丁烯，m为1至300（最好为2至300），聚醚与一个或多个基团链相连，这些基团最好选择自一个或多个可选择地取代的直链或支链C1至C10烷基、氨基、醚基、酯基、酰胺基、碳酸酯基和碳酸酯基；A在每次出现时可以相同也可以不同，表示包含一个末端官能团，该官能团包括一个包含炔烃或叠氮官能团的基团，其中所述末端官能团与式(I)的X的末端官能团互补，从X和A的反应中提供三唑基团。
• Polymer conjugate comprising a bioactive agent
  申请人：POLYACTIVA PTY LTD

  公开号：US10758626B2

  公开（公告）日：2020-09-01

  The present invention relates in general to polymer-bioactive agent conjugates for delivering a bioactive agent to a subject. The polymer-bioactive agent conjugates contain triazole moieties in the polymer backbone and a bioactive moiety selected from quinolones, NSAIDs and mixtures thereof. The present invention also relates to methods for preparing the polymer conjugates using click cycloaddition chemical reactions, to monomer-bioactive agent conjugates suitable for preparing the polymer conjugates, and to pharmaceutical products comprising the polymer conjugates for the post-surgical care to treat or prevent infections, provide analgesia and treat inflammation.

  本发明总体上涉及用于向受试者输送生物活性剂的聚合物-生物活性剂共轭物。聚合物-生物活性剂共轭物的聚合物骨架中含有三唑分子和选自喹诺酮类、非甾体抗炎药及其混合物的生物活性分子。本发明还涉及使用单击环化化学反应制备聚合物共轭物的方法、适用于制备聚合物共轭物的单体-生物活性剂共轭物，以及包含聚合物共轭物的用于手术后治疗或预防感染、提供镇痛和治疗炎症的药物产品。
• POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT
  申请人：POLYACTIVA PTY LTD

  公开号：EP3347052A1

  公开（公告）日：2018-07-18
• BIODEGRADABLE DRUG-POLYMER CONJUGATE
  申请人：POLYACTIVA PTY LTD

  公开号：US20200123322A1

  公开（公告）日：2020-04-23

  A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, β-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.